This site is intended for healthcare professionals

FDA approves a new formulation of Ultomiris with significantly reduced infusion time for for patients with aHUS and PNH.- Alexion Pharma

Read time: 1 mins
Last updated:28th Jun 2021
Published:22nd Oct 2020
Condition: Paroxysmal Nocturnal Haemoglobinuria
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest